Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03423628 · ClinicalTrials.gov registry record · Phase 1
A Study to Assess the Safety and Tolerability of AZD1390 Given With Radiation Therapy in Patients With Brain Cancer
A Phase 1 study of Recurrent Glioblastoma Multiforme and Primary Glioblastoma Multiforme, sponsored by AstraZeneca.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 180
- Enrollment target
- 12
- Study locations
NCT03423628: Recruiting Phase 1 study of Recurrent Glioblastoma Multiforme and Primary Glioblastoma Multiforme, sponsored by AstraZeneca.
NCT03423628 is a Phase 1 study of Recurrent Glioblastoma Multiforme and Primary Glioblastoma Multiforme that is actively recruiting participants, run by AstraZeneca. The registered enrollment target is 180 participants, above the 74-participant average among 6 other Recurrent Glioblastoma Multiforme trials with a reported enrollment target (143% higher). The trial reports 12 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03423628, a Phase 1 study of Recurrent Glioblastoma Multiforme and Primary Glioblastoma Multiforme, is actively recruiting participants, sponsored by AstraZeneca.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 180 participants
- Enrollment target
- 12
- Study locations
Study Summary
This study will test an investigational drug called AZD1390 in combination with radiation therapy for the treatment of brain tumors. This is the first time AZD1390 is being given to patients. This study will test safety, tolerability and PK (how the drug is absorbed, distributed and eliminated) of ascending doses of AZD1390 in combination with distinct regimens of radiation therapy
Primary Outcome
DLTs will be used to calculate the maximum tolerated dose (MTD). In each arm, the MTD of AZD1390 is the highest dose at which the predicted probability of a DLT is less than 25% in that specific RT setting
Conditions Studied
Interventions
- RADIATION Radiation Therapy
- DRUG AZD1390
Study Locations (12)
Other
- Research Site - Chūōku
- Research Site - Hidaka-shi
- Research Site - Kyoto
- Research Site - Cambridge
- Research Site - Glasgow
- Research Site - Leeds
- Research Site - London
Massachusetts
- Research Site - Boston
- Research Site - Boston
New York
- Research Site - New York
Pennsylvania
- Research Site - Pittsburgh
Virginia
- Research Site - Richmond
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 180 participants |
| Start Date | 2018-04-02 |
| Est. Completion | 2026-09-16 |
| Phase | Phase 1 |
What NCT03423628 shows while recruiting
NCT03423628 is an interventional study that assigns participants to a tested intervention. The registered 180 participants enrollment target is mid-sized for trials with a published cap, above the 74-participant average among 6 other Recurrent Glioblastoma Multiforme trials with a reported enrollment target (143% higher).
The record links to 4 conditions, with Recurrent Glioblastoma Multiforme appearing as the primary indexed condition, and to 2 interventions - of which Radiation Therapy is the first listed.
NCT03423628 lists 12 locations in 5 states (Other, Massachusetts, New York).
Frequently Asked Questions
What is clinical trial NCT03423628 about?
NCT03423628 is a clinical study titled "A Study to Assess the Safety and Tolerability of AZD1390 Given With Radiation Therapy in Patients With Brain Cancer". This study will test an investigational drug called AZD1390 in combination with radiation therapy for the treatment of brain tumors. This is the first time AZD1390 is being given to patients. This study will test safety, tolerability and PK (how the drug is absorbed, distributed and eliminated) of a...
What is the current status of trial NCT03423628?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 180 participants. The study started on 2018-04-02. Estimated completion is 2026-09-16.
What conditions does trial NCT03423628 study?
This clinical trial studies the following conditions: Recurrent Glioblastoma Multiforme, Primary Glioblastoma Multiforme, Brain Neoplasms, Malignant, Leptomeningeal Disease (LMD).
What interventions are being tested in trial NCT03423628?
The interventions under investigation include: Radiation Therapy (RADIATION), AZD1390 (DRUG).
Who is sponsoring clinical trial NCT03423628?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03423628 being conducted?
This trial has 12 study locations across Massachusetts, New York, Pennsylvania, Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Recurrent Glioblastoma Multiforme
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Genetically Engineered HSV-1 Phase 1 Study for the Treatment of Recurrent Malignant Glioma
ACTIVE NOT RECRUITING · Phase 1
-
Monteris AutoLITT™ FIM Safety Trial for Recurrent/Progressive Brain Tumors
COMPLETED · Phase 1
-
Phase Ib, Dose Escalation Study of Oral LDE225 in Combination With BKM120 in Patients With Advanced Solid Tumors
COMPLETED · Phase 1
-
Phase 2 Study of Panzem Nanocrystal Colloidal Dispersion (NCD) in Combination With Fixed-Dose Temozolomide to Patients With Recurrent Glioblastoma Multiforme (GBM)
COMPLETED · Phase 2
-
Ph. 2 Sorafenib + Protracted Temozolomide in Recurrent GBM
COMPLETED · Phase 2
-
Effect of NovoTTF-100A in Recurrent Glioblastoma Multiforme (GBM)
COMPLETED · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01558804 · 180 participants
GRoup A StrePtococcus
- NCT02932176 · 180 participants
Machine Learning for Handheld Vascular Studies
- NCT03384563 · 180 participants · Phase 4
Effect of Dexmedetomidine on the Minimum Alveolar Concentration of Sevoflurane
- NCT03610763 · 180 participants · NA
Harnessing Neuroplasticity to Enhance Functional Recovery During Chronic Recovery From Upper Extremity Nerve Repair
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI